Innate Pharma (OTCMKTS:IPHYF – Get Free Report) is anticipated to post its results before the market opens on Thursday, September 17th. Analysts expect Innate Pharma to post earnings of ($0.2912) per share and revenue of $6.2810 million for the quarter.
Innate Pharma Stock Performance
Innate Pharma stock opened at $1.65 on Wednesday. The company’s 50-day moving average price is $1.65 and its 200-day moving average price is $1.70. Innate Pharma has a twelve month low of $1.37 and a twelve month high of $2.25.
Innate Pharma Company Profile
Innate Pharma SA is a France-based biotechnology company focused on developing immunotherapies for cancer. The company’s research is centered on the innate immune system, including natural killer cells and other immune mechanisms that can recognize and attack tumor cells. Its activities include drug discovery, clinical development and collaborations with pharmaceutical companies.
Innate Pharma’s pipeline has included antibody-based therapies designed to stimulate or direct immune responses against cancer.
Further Reading
- Five stocks we like better than Innate Pharma
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
